Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Deficiency) (Tables)

v3.24.1.1.u2
Stockholders' Equity (Deficiency) (Tables)
12 Months Ended
Mar. 31, 2023
Stockholders' Equity (Deficiency)  
Summary of stock-based compensation expense by statement of operations line item

The following table summarizes, by consolidated statements of operations line item, stock-based compensation expense (in thousands):

Year Ended

March 31,

    

2023

    

2022

 

Cost of goods sold

$

37

    

$

109

Research and development

 

97

 

79

Selling, general and administrative

 

729

 

1,057

Stock-based compensation expense

$

863

$

1,245

Summary of stock option activity

Weighted

Average Grant

Date Fair

Restricted Stock Units and Performance Restricted Stock Units

Shares

Value

 

Non-vested restricted stock units outstanding at March 31, 2022

    

591,805

    

$

5.66

Granted

 

646,814

2.04

Vested and issued

 

(179,471)

5.76

Forfeited

 

(216,517)

4.54

Non-vested restricted stock units outstanding at March 31, 2023

 

842,631

3.13

Restricted stock units expected to vest beyond March 31, 2023

 

842,631

$

3.13

Summary of restricted stock activity

The following table provides additional information on restricted stock units and performance restricted stock units:

Year Ended March 31,

    

2023

    

2022

Restricted stock compensation expense (in thousands)

    

$

863

    

$

1,245

Aggregate fair value of restricted stock units vested and issued (in thousands)

    

$

477

    

$

936

Weighted average grant date fair value of restricted stock units granted during the period

    

$

2.29

    

$

5.40

Schedule of fair value assumptions - warrants

Risk-free interest rate

 

0.2%

Contractual term

 

3 years

Expected volatility

 

81.0%